Clinical Trial Update: Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions [Phase 2]

View source ↗

Summary

Phase 2 study of tarloxotinib in NSCLC with EGFR Exon 20 insertion or HER2-activating mutations and other solid tumors with NRG1/ERBB fusions was terminated; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarloxotinib (tarloxotinib)

Snippet

Sponsor: Rain Oncology Inc | Conditions: NSCLC, Stage IV, NSCLC Stage IIIB | Phase 2 | Status: TERMINATED | Results posted: 2023-06-28